Effect of HLJG0701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Hwajin0 个研究点目标入组 80 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(1.0SD<= and 2.0SD < CERAD-K memory score) comparing to the same age and education group.

•- People who are currently suffering from schizophrenia or have a history of schizophrenia
•- People who have major depressive disorders categorized by DSM-V(The Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition)
•- People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on DSM-V)
•- People who have taken medications for Alzheimer’s disease or other cognitive function problems within 4 weeks prior to the first visit of the study. The examples of the medications are Antipsycotics, Neurodegenerative Disease Drugs, Nootropics & Neurotonics, and tricyclic antidepressant.

发起方

Hwajin